

**Priority question for written answer P-000919/2025
to the Commission**

Rule 144

Martin Häusling (Verts/ALE)

Subject: GGSC opinion on NGTs – shift of safety assessment and liability risks from biotech companies to the food industry

The recent legal opinion by the Berlin law firm GGSC on the planned deregulation of new genomic techniques (NGTs) shows that the legislation proposed by the Commission will shift the safety assessment and liability risks for plants produced with NGTs and products derived from them from biotech companies to the food industry. The opinion points to the risk that the entire EU food sector might be in breach of the Commission's legislative proposal¹.

1. Does the Commission agree that large companies are able to cope more easily with the burdens imposed on them under the Novel Food Regulation than small and medium-sized enterprises, and that the latter are penalised as a result?
2. Has the Commission analysed the burden and costs for food companies of the requirement to carry out safety assessments on NGT1 plants under the Novel Foods Regulation, and what is the extent of this burden and of these costs according to the Commission?
3. Is the Commission planning an impact assessment in relation to its proposed legislation to regulate NGT, which seeks to shift the burden and cost of safety assessments of NGT1 plants from biotech companies to the food sector?

Submitted: 5.3.2025

¹ https://www.ohnegentechnik.org/fileadmin/user_upload/08_presse/VLOG_GGSC-Rechtsgutachten_Haftung_bei_NGT-Deregulierung_Januar_2025.pdf